Validating Momentum: PRIME Publication and Emerging Commercial Proof Points Support Sera’s Buy Rating Despite Adoption Risks

William Blair analyst Andrew Brackmann has maintained their bullish stance on SERA stock, giving a Buy rating on February 4.

Andrew Brackmann has given his Buy rating due to a combination of factors tied to Sera’s recent clinical and commercial progress. He views the peer‑reviewed publication of the PRIME study as a key validation milestone that strengthens the clinical and economic case for the company’s PreTRM test and, importantly, equips Sera with robust evidence to engage payers and large provider systems on reimbursement and adoption.

He also highlights that, while test utilization is likely to ramp gradually, early signals of physician interest and conference engagement suggest building momentum that could translate into broader demand ahead of formal guideline inclusion. Brackmann expects incremental proof points over 2026—such as commercial payer contracts, advances in Medicaid pilot programs, and growing awareness—to steadily de‑risk the story, supporting an Outperform (Buy) stance despite acknowledged execution and adoption risks.

In another report released on February 4, TipRanks – Google also upgraded the stock to a Buy with a $3.00 price target.